{"DataElement":{"publicId":"5823194","version":"1.1","preferredName":"Treatment Cohort Study 10042 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10042 in which subsets of a defined population are identified.","longName":"TX_COH_10042_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5823180","version":"1.1","preferredName":"10042 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"5823180v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"SG1","valueDescription":"SG1: T790M mutation positive, new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","ValueMeaning":{"publicId":"5823181","version":"1","preferredName":"SG1: T790M mutation positive, new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","longName":"5823181","preferredDefinition":"SG1: T790M mutation positive, new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5876CD-D248-5950-E053-F662850A5AC2","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1AB2-3F1B-E053-F662850A0A01","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG10","valueDescription":"SG10: EGFR mutation (L858R/other), new or progressing brain metastases (less than 4) and performance status (2)","ValueMeaning":{"publicId":"6686075","version":"1","preferredName":"SG10: EGFR mutation (L858R/other), new or progressing brain metastases (less than 4) and performance status (2)","longName":"6686075","preferredDefinition":"SG10: EGFR mutation (L858R/other), new or progressing brain metastases (less than 4) and performance status (2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1B4F-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1B68-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG9","valueDescription":"SG9: EGFR mutation (L858R/other), new or progressing brain metastases (greater than or equal to 4) and performance status (2)","ValueMeaning":{"publicId":"6686076","version":"1","preferredName":"SG9: EGFR mutation (L858R/other), new or progressing brain metastases (greater than or equal to 4) and performance status (2)","longName":"6686076","preferredDefinition":"SG9: EGFR mutation (L858R/other), new or progressing brain metastases (greater than or equal to 4) and performance status (2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1B72-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1B8B-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG8","valueDescription":"SG8: EGFR mutation (L858R/other), new or progressing brain metastases (less than 4) and performance status (0-1)","ValueMeaning":{"publicId":"6686077","version":"1","preferredName":"SG8: EGFR mutation (L858R/other), new or progressing brain metastases (less than 4) and performance status (0-1)","longName":"6686077","preferredDefinition":"SG8: EGFR mutation (L858R/other), new or progressing brain metastases (less than 4) and performance status (0-1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1B95-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1BAE-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG7","valueDescription":"SG7: EGFR mutation (L858R/other), new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","ValueMeaning":{"publicId":"6686078","version":"1","preferredName":"SG7: EGFR mutation (L858R/other), new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","longName":"6686078","preferredDefinition":"SG7: EGFR mutation (L858R/other), new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1BB8-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1BD1-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG6","valueDescription":"SG6: T790M mutation negative, new or progressing brain metastases (less than 4) and performance status (0-1)","ValueMeaning":{"publicId":"5858931","version":"1","preferredName":"SG6: T790M mutation negative, new or progressing brain metastases (less than 4) and performance status (0-1)","longName":"5858931","preferredDefinition":"SG6: T790M mutation negative, new or\r\nprogressing brain metastases (less than 4) and\r\nperformance status (0-1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5161A67C-4946-6665-E053-F662850AEE2A","latestVersionIndicator":"Yes","beginDate":"2017-06-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1AE4-3F1B-E053-F662850A0A01","beginDate":"2017-06-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG5","valueDescription":"SG5: EGFR mutation (exon 19 deletion), new or progressing brain metastases (less than 4) and performance status (2)","ValueMeaning":{"publicId":"6686079","version":"1","preferredName":"SG5: EGFR mutation (exon 19 deletion), new or progressing brain metastases (less than 4) and performance status (2)","longName":"6686079","preferredDefinition":"SG5: EGFR mutation (exon 19 deletion), new or progressing brain metastases (less than 4) and performance status (2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1BDB-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1BF4-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG4","valueDescription":"SG4: EGFR mutation (exon 19 deletion), new or progressing brain metastases (greater than or equal to 4) and performance status (2)","ValueMeaning":{"publicId":"6686080","version":"1","preferredName":"SG4: EGFR mutation (exon 19 deletion), new or progressing brain metastases (greater than or equal to 4) and performance status (2)","longName":"6686080","preferredDefinition":"SG4: EGFR mutation (exon 19 deletion), new or progressing brain metastases (greater than or equal to 4) and performance status (2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1BFE-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1C17-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG3","valueDescription":"SG3: EGFR mutation (exon 19 deletion), new or progressing brain metastases (less than 4) and performance status (0-1)","ValueMeaning":{"publicId":"6686081","version":"1","preferredName":"SG3: EGFR mutation (exon 19 deletion), new or progressing brain metastases (less than 4) and performance status (0-1)","longName":"6686081","preferredDefinition":"SG3: EGFR mutation (exon 19 deletion), new or progressing brain metastases (less than 4) and performance status (0-1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1C21-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1C3A-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"SG2","valueDescription":"SG2: EGFR mutation (exon 19 deletion), new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","ValueMeaning":{"publicId":"6686082","version":"1","preferredName":"SG2: EGFR mutation (exon 19 deletion), new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","longName":"6686082","preferredDefinition":"SG2: EGFR mutation (exon 19 deletion), new or progressing brain metastases (greater than or equal to 4) and performance status (0-1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1C44-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A24CC1-1C5D-3F1B-E053-F662850A0A01","beginDate":"2019-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A24CC1-1A9C-3F1B-E053-F662850A0A01","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"SOKKERL","dateModified":"2019-04-03","changeDescription":"version due to updated and added new  Pvs 4/3/19 ls.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient Subgroup","type":"Preferred Question Text","description":"Patient Subgroup","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A23D81-62D0-59FF-E053-F662850AF221","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"SOKKERL","dateModified":"2019-04-03","changeDescription":"5/12/2017 LS    versioned VD 4/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}